AKT1 and diabetes mellitus: Xiong et al. [57] considered ergosterol as a potential hypoglycemic agent for the treatment of type 2 diabetes mellitus based on the discovery that it could promote glucose transporter type 4 translocation and expression, as well as glucose uptake via the PI3K (phosphatidylinositol 3-kinase) and Akt (protein kinase B) pathways.